Compare NextEra Energy, Inc. (NEE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? NextEra Energy, Inc. trades at $77.46 (market cap $160.75B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: NextEra Energy, Inc. is far larger — about 2.1× Regeneron Pharmaceuticals Inc's market cap, and NextEra Energy, Inc. pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| NEE | REGN | |
|---|---|---|
Market Cap | $160.75B | $76.40B |
Volume | 10,598,021 | 626,381 |
Sector | Utilities | Health |
52-Week High | $97.88 | $852.03 |
52-Week Low | $75.49 | $557.73 |
Typical Hold Time | 83 Days | 107 Days |
Enterprise Value | $268.08B | $71.12B |
Dividend Yield | 3.23% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $77.37, down 0.65% with a bearish technical signal. The stock shows strong fundamentals with 32.4% net income margin and 17.23% ROE, though recent earnings were mixed with a Q4 miss but Q1-Q2 beats. Analyst consensus remains bullish with 66.7% buy ratings and $96 price target. Recent news highlights growth opportunities including a $22.3 billion energy infrastructure partnership and 18 GW gas development prospects.
NEE presents a compelling long-term investment case with robust profitability and analyst support, though near-term technical weakness and rising debt levels warrant caution. The company's clean energy transition strategy and infrastructure projects provide growth catalysts, but interest rate sensitivity and execution risks on large projects represent key challenges for investors.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
